Fortress Biotech Q3 rev up 20.5% to $17.6mln, Checkpoint Therapeutics acquired.

• Fortress Biotech Q3 revenue up 20.5% to $17.6 million • Checkpoint Therapeutics acquired by Sun Pharma for ~$28 million • Fortress eligible for up to $4.8 million in contingent payments • Crystalys Therapeutics raises $205 million in Series A financing • Dotinurad advancing in two Phase 3 clinical trials • Potential for best-in-class safety and efficacy for Dotinurad